FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function in type 1 diabetes.
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain individuals recently diagnosed with T1D.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for at-risk individuals.
Investigations by Leading Immune-Mediated Disease Research Organizations
Breakthrough T1D has partnered with the Lupus Research Alliance and the National Multiple Sclerosis Society to advance the understanding of autoimmunity.
Can a Psoriasis Drug Halt or Reverse Type 1 Diabetes?
Type 1 diabetes is one of the only major autoimmune diseases that doesn't have a disease-modifying therapy. A Breakthrough T1D clinical trial is aiming to change that.
It’s Official: Teplizumab is Under Review by the FDA
The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target action date is July 2, 2021.
Discovery to Translation: Clinical Trial of a JAK Inhibitor in T1D
A Breakthrough T1D-funded clinical trial will test if a JAK inhibitor will preserve beta cell function in children and young adults with recently diagnosed T1D.
